POLPHARMA-BIOLOGICS
Polpharma Biologics Group announces that its joint venture company with Santo Holding (Strüngmann Group), Bioeq, has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis® ).
The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) used to treat various types of macular-degenerative diseases such as neovascular (wet) age-related macular degeneration, diabetic retinopathy, macular edemas and myopic choroidal neovascularization. Worldwide, at least 25 to 30 million people are affected by age-related macular degeneration. The launch of a biosimilar Ranibizumab can increase market competition, reduce cost and expand patient access with proven analytical and clinical similarity to the original product. It works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.
Subject to FDA's approval of this BLA, the product will be exclusively commercialized by Coherus BioSciences, Inc. in the United States.
Said submission represents the most recent milestone for Bioeq's ranibizumab biosimilar program and compliments marketing authorization applications submitted to EMA and UK MHRA already in July this year.
Dr Joerg Windisch, CEO of the Polpharma Biologics Group, commented:
“The submission of a BLA to the FDA is a major milestone for any therapeutic and brings hope to patients across the US. This announcement carries a tangible promise of treatment choice and improved access to those who suffer from debilitating vision loss, including age-related macular degeneration. This is another representation of our commitment to providing safe and effective medicines to patients.”
1) Lucentis ® is a registered trademark of Genentech Inc.
About Ranibizumab biosimilar
The Ranibizumab biosimilar, previously designated as FYB201 (and also known as CHS-201), has been originally licensed from Formycon AG (FRA: FYB/ WKN A1EWVY), a leading German biosimilars company, and subsequently developed by Bioeq AG, a joint venture between Polpharma Biologics and Santo Holding AG (Strüngmann Group). Phase III clinical trials for FYB201 have clinically demonstrated that the efficacy of FYB201 in patients with nAMD is comparable to that of Lucentis® .
About biosimilars
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Biosimilars exhibit proven analytical and clinical similarity to their respective branded reference products.
About Polpharma Biologics Group
The Polpharma Biologics Group creates quality biosimilars with a passion to improve lives of patients. The group has built an extensive and growing pipeline of biosimilars to treat a number of medical conditions across major therapeutic areas. Several of these biosimilar assets have already been commercially partnered with the world’s largest biopharmaceutical companies.
The group operates a network of state-of-the-art development and manufacturing facilities across Europe, actively investing in technology, people and know-how, employing over 800 specialists from around the globe.
Learn more at www.polpharmabiologics.com
About Bioeq
Bioeq is a Swiss biopharmaceutical joint venture between the Polpharma Biologics Group and the Strüngmann Group. Bioeq develops, licenses and commercializes biosimilars.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005187/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daikin Leverages DataXstream’s OMS+ to Take Customer Experience to New Heights2.12.2025 16:03:00 CET | Press release
SAP-native platform will empower Daikin to reduce complexity, elevate the in-store/online customer experience, and optimize order accuracy across all locations DataXstream LLC, an SAP® Endorsed App partner developing intelligent solutions for SAP sales and distribution, announced today that Daikin Comfort Technologies North America, Inc. (Daikin), a subsidiary of Daikin Industries Ltd. and leading HVAC manufacturer, has selected its OMS+ platform to deliver real-time point-of-sales capabilities, along with an intuitive, streamlined order management to transform Daikin’s in-store and online customer experience. Leveraging SAP solutions, Daikin and DataXstream are elevating the way customers engage with Daikin’s stores and brand by delivering unparalleled, consistent point-of-sale capabilities, along with real-time visibility of orders and inventory across all sales channels. “Customers want a consistent and responsive experience, regardless of where they place their order,“ said Tim Yat
Halo Infinite and Elysium Senior Concept Designer Ben Mauro Launches HUXLEY: The Oracle - Sci-Fi Prequel Debuts as #1 Amazon New Release2.12.2025 16:00:00 CET | Press release
Ben Mauro, the acclaimed concept artist and worldbuilder behind Halo Infinite, Call of Duty, Elysium, and The Predator, today announced the US release of HUXLEY: The Oracle. The book, serving as the narrative prequel to Mauro’s expanding HUXLEY universe, has already reached #1 in Amazon’s New Releases for Conceptual Art based on pre-orders alone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202609807/en/ HUXLEY: The Oracle Cover illustration HUXLEY: The Oracle departs from the graphic novel format in the first book, adopting an immersive narrative art book format that pairs cinematic, full-page illustrations alongside storytelling. Using a format familiar to readers of Simon Stålenhag’s Tales from the Loop, the book places world-building at the forefront, delivering a large-scale, atmospheric introduction to the world of HUXLEY that is fitting to the new story. HUXLEY: The Oracle unites a "dream team" of industry heavyw
Ullevaal Stadium Among the First in the World to Install FIFA Quality Pro Certified LED Lighting System2.12.2025 15:15:00 CET | Press release
A newly installed, state-of-the-art LED lighting system at Ullevaal Stadium has transformed the playing, viewing, and entertainment experience for athletes and spectators, and has made Norway’s national stadium one of the few in the world with FIFA Quality Pro Certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201171907/en/ The state-of-the-art TLC for LED® lighting system at Ullevaal Stadium has made Norway’s national stadium one of the few in the world with FIFA Quality Pro Certification. Home to Norway’s national football team, Ullevaal Stadium opened in 1926 and has a rich history of hosting significant sporting and entertainment events. When stadium ownership at the Football Association of Norway (NFF) decided to upgrade the venue’s lighting, they envisioned a system with the most advanced LED technology for the best possible playing, viewing, and entertainment experience. “Our main priorities for the new
Logical Intelligence Achieves 76 Percent on Putnam Benchmark, Highlighting Shift Beyond Large Language Models to Language-free, Mathematically Grounded Models2.12.2025 15:15:00 CET | Press release
Over the last decade, artificial intelligence (AI) has been largely built around large language models (LLMs). These systems are based on a language and guess words in a chain in the form of tokens. As a result, they frequently hallucinate and require vast compute and power infrastructure to solve tasks. The moment systems like public safety, national infrastructure, and industrial automation need logic, LLMs break and introduce safety risks. Token-free language independent models represent a new direction for AI. They do not predict words. They search for correct solutions and require less compute. Logical Intelligence is the first company building exclusively around mathematically derived, non autoregressive EBM (Energy Based Model) reasoning. Today, Logical Intelligence announced that its Aleph tool achieved a 76 percent score on the Putnam Benchmark, one of the most demanding mathematical reasoning tests in artificial intelligence. The benchmark measures a model’s ability to solve
MUSASHI JAPAN Launches “Gift Campaign 2025” - A Holiday Tradition Honoring Craftsmanship Through Meaningful Gifts2.12.2025 15:07:00 CET | Press release
MUSASHI JAPAN by TAIMATSU announces the return of its year-end celebration, Gift Campaign 2025, a seasonal tradition that transforms holiday shopping into an experience of appreciation, craftsmanship, and cultural generosity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202812444/en/ Rather than focusing on discounts, MUSASHI embraces the philosophy that true value lies in tools that last and in the gestures that accompany them. This year’s campaign invites customers to discover gifts that enrich their craft in the kitchen, each thoughtfully chosen to support the longevity and performance of every Musashi blade. Inspired by the Japanese principle of omotenashi, the campaign offers customers tiered gifts based on their total purchase amount, ensuring that every contribution is met with gratitude and purpose. From December 2 to December 25, 2025, customers shopping in MUSASHI JAPAN stores will receive: Tier 1: Oil and Rus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom